secwatch.observer — SEC 8-K summary
======================================

Issuer:     Opus Genetics, Inc. (IRD)
CIK:        0001228627
Form:       8-K
Filed at:   2026-08-06T11:04:40+00:00
Accession:  0001628280-26-053824
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Opus Genetics Q2 net loss $8.1M; LCA5 trial enrollment completed
----------------------------------------------------------------

- Net loss of $8.1M ($0.08 basic EPS) vs $7.4M loss in Q2 2025; revenue fell to $0.8M from $2.9M.
- Cash and equivalents $88.8M; runway into 2029, excluding potential warrant proceeds or milestones.
- OPGx-BEST1 Cohort 1 topline data expected second week of September 2026.
- OPGx-LCA5 registrational trial enrollment completed; dosing expected Q4 2026 with topline data by end of 2027.
- OPGx-RDH12 enters clinic Q4 2026; OPGx-MERTK clinical testing Q1 2027; OPGx-RHO clinical testing H2 2027.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1228627/000162828026053824/0001628280-26-053824-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1228627/000162828026053824/ird-20260806.htm
  HTML page:      https://secwatch.observer/filing/0001628280-26-053824

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer